Jeff Sunman

Precision BioSciences is expanding its global Phase 1 ELIMINATE‑B trial evaluating PBGENE‑HBV following clinical trial application approval in two European countries. “Expanding ELIMINATE-B into hepatitis sites in France and Romania is an important step in the continued development of PBGENE-HBV, the only gene editing therapy uniquely designed to eliminate cccDNA,” said Cindy Atwell, Chief Development and Business Officer of Precision BioSciences. “Given the strong investigator interest in PBGENE-HBV, especially following the late breaker oral presentation at The Liver Conference 2025, these new trial sites will build on our existing global clinical trial footprint as we advance PBGENE-HBV through the ELIMINATE-B trial.” To learn more, visit loom.ly/ore3n7A $DTIL

Lots of free hockey tonight in Raleigh. #2OT

Game 2 with a couple of Precision buds 😎 #LetsGoCanes

Only one chance in this lifetime… Like watching sunset at the beach from the most foreign seat in the cosmos, I couldn’t resist a cell phone video of Earthset. You can hear the shutter on the Nikon as @Astro_Christina is hammering away on 3-shot brackets and capturing those exceptional Earthset photos through the 400mm lens. @AstroVicGlover was in window 3 watching with @Astro_Jeremy next to him. I could barely see the Moon through the docking hatch window but the iPhone was the perfect size to catch the view…this is uncropped, uncut with 8x zoom which is quite comparable to the view of the human eye. Enjoy.

Apex doing the most Apex of things today, raising the tank of a new water tower.

Precision BioSciences was proud to join the 2026 MDA Clinical & Scientific Conference last month, where the team presented new preclinical data on PBGENE‑DMD, the company’s in vivo gene editing candidate designed to restore near full‑length dystrophin and potentially benefit boys with mutations between exons 45–55. As Debra Miller of CureDuchenne noted, “IND clearance for PBGENE‑DMD is an exciting step forward, and we look forward to collaborating to help connect innovation with the patient families we serve.” Read the full release, loom.ly/-wqqxIk

Fun night of pick up curling @trianglecurling before helping the bunny hide all the eggs.

Call the timeout Duke 🤷‍♂️

😈

Precision BioSciences announced its Q4 and fiscal year 2025 earnings and provided a business update! CFO, Alex Kelly, tells you what you need to know. Read the full press release, investor.precisionbiosciences.com/news-releases/… #GeneEditing #Biotech $DTIL

From the podium to the photo wall, the Precision BioSciences team is making the most of TD Cowen’s 46th Annual Health Care Conference! Cassie Gorsuch, PhD, Chief Scientific Officer, Alex Kelly, Chief Financial Officer, and Naresh Tanna, Head of Investor Relations, highlighted the company's focused in vivo gene editing strategy and upcoming milestones for our wholly owned programs in chronic hepatitis B and Duchenne muscular dystrophy. Want to watch the presentation replay? Visit loom.ly/eyoTv2Y $DTIL

Precision BioSciences announced that it has earned a clinical development milestone payment of $7.5 million from TG Therapeutics for the ongoing development of azer-cel in multiple sclerosis. The payment was triggered as a result of progress in TG Therapeutics' Phase 1 study evaluating azer-cel in adults with relapsing forms of multiple sclerosis, which is being conducted under its license agreement with Precision. The milestone payment is expected to support Precision’s cash runway through 2028 and further advancement of the company’s wholly owned in vivo gene editing programs. Read the full release, loom.ly/ejTCLls

Precision BioSciences has received a U.S. FDA “Study May Proceed” notification for its investigational new drug (IND) application for PBGENE‑DMD, enabling initiation of clinical trial site activation for the Phase 1/2 FUNCTION‑DMD clinical study in patients with Duchenne muscular dystrophy (DMD). PBGENE‑DMD is Precision’s wholly owned, first‑in‑class in vivo gene editing investigational product designed to correct the underlying genetic cause of DMD through a novel one‑time gene editing therapy targeting mutations between exons 45 and 55, the “hot‑spot” region accounting for approximately 60% of boys with DMD. PBGENE‑DMD has been granted U.S. FDA Rare Pediatric Disease and Orphan Drug designations for the treatment of DMD. Read the full release, loom.ly/s6wbj-k

Celebrating 20 years of Precision! Last week, our team of “Precisioneers” came together to reflect on two decades of advancing gene-editing science and the progress we’re making toward new in vivo therapies for conditions such as chronic hepatitis B and Duchenne muscular dystrophy. As a clinical-stage gene editing company, we’re using our proprietary ARCUS platform to develop one-time, potentially durable treatments aimed at overcoming hard-to-treat genetic and infectious diseases. Here’s to our future of hope, and to the patients, partners, and colleagues who inspire us to keep pushing the science forward. $DTIL

UNBELIEVABLE!! I remember taking that first trip to Bloomington with the kiddo in 2023 and saying how atrocious their football team was. It’s just unreal. Have fun tonight kiddo. #NeverDaunted

What a time to have sent a kid to this school 😄 #Indiana #Hoosiers

My college kid strongly dislikes the Rangers and I’m here for it. #Canes

Precision BioScience is proud to share new data at #AASLD2025 for PBGENE-HBV, our first-in-class gene editing therapy for chronic hepatitis B, presented by Man-Fung Yuen, MBBS, M.D., PhD, DSc, ELIMINATE-B Investigator, Chair Professor of The University of Hong Kong, and the Chief of the Division of Gastroenterology and Hepatology at Queen Mary Hospital. These new late-breaking data represent a milestone for Precision BioSciences and for the entire field of chronic Hepatitis B because it is the first time clinicians have been able to target the root viral source of the disease. The safety data and tolerability profile, along with dose-dependent durable reductions in hepatitis B surface antigen and the first-ever liver biopsy data provide evidence that antiviral activity is being achieved through directly editing the viral genome in patients with chronic Hepatitis B. This further validates ARCUS as a differentiated platform with true curative potential. With no observed dose-limiting toxicities, we look forward to finishing dosing the third cohort to generate additional data for PBGENE-HBV in our pursuit of a cure that has been so elusive in the field of Hepatitis B drug development. Thank you to all of our investigators, collaborators, and patients who help drive this important progress. More updates to come as we push toward new standards of care for HBV. For more information, visit loom.ly/nrE9gr4 #GeneEditing #HBV #AASLD #Biotech #PrecisionBioSciences #DTIL

BUILD THE OMAR COOPER STATUE

Just unbelievable. #IU #Indiana #HOOSIERS